间氨基氯苄 | 65581-20-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 间氨基氯苄
• 英文名称: 3-Chlormethyl-anilin
• 英文别名: 3-(Chloromethyl)aniline
• CAS: 65581-20-6
• 化学式: C₇H₈ClN
• mdl: MFCD11870125
• 分子量: 141.6
• InChiKey: BWDPPMPQZZILAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2921420090

反应信息

• 作为反应物：
  描述：

  间氨基氯苄 、 5,6-二氯-[1,2,5]恶二唑并[3,4-B]吡嗪 在 N,N-二乙基苯胺 作用下， 以 乙腈 为溶剂， 以56%的产率得到5-N,6-N-bis[3-(chloromethyl)phenyl]-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine
  参考文献：
  名称：

  呋喃并[3,4-b]吡嗪的化学

  摘要：

  DOI：

  10.1007/bf02290874

文献信息

• [EN] METHODS OF MODULATING LEUKOCYTES ACTIVATION AND THROMBOCYTE CLEARANCE WITH INHIBITORS OF SPECIFIC NEURAMINIDASE ISOENZYMES<br/>[FR] MÉTHODES DE MODULATION DE L'ACTIVATION DES LEUCOCYTES ET DE LA CLAIRANCE DES THROMBOCYTES AVEC DES INHIBITEURS D'ISOENZYMES DE NEURAMINIDASE SPÉCIFIQUES
  申请人：PCHEJETSKI ALEXEY

  公开号：WO2020107124A1

  公开（公告）日：2020-06-04

  The present invention provides a method of modulating leukocytes activation (e.g., adhesion and/or transmigration and/or cytokine response) and a method of modulating thrombocyte clearance comprising administering to a subject in need thereof a specific inhibitor of neuraminidase 1 (neu1); neuraminidase 3 (neu3) or neuraminidase 4 (neu4); or a bispecific inhibitor of neu1, neu3 or neu4 of formula (I): (I) Also provided are pharmaceutical compositions comprising the inhibitor compound of formula (1), and uses thereof for modulating leukocytes activation or modulating thrombocyte clearance.

  本发明提供了一种调节白细胞活化（例如，粘附和/或跨膜迁移和/或细胞因子反应）的方法，以及一种调节血小板清除的方法，包括向需要的受试者施用神经氨酸酶1（neu1）的特异性抑制剂；神经氨酸酶3（neu3）或神经氨酸酶4（neu4）；或式（I）的神经氨酸酶1、神经氨酸酶3或神经氨酸酶4的双特异性抑制剂：（I）。还提供了包括式（1）的抑制剂化合物的药物组合物，以及用于调节白细胞活化或调节血小板清除的用途。
• [EN] METHODS OF PREVENTING OR TREATING ATHEROSCLEROSIS WITH INHIBITORS OF SPECIFIC ISOENZYMES OF HUMAN NEURAMINIDASE<br/>[FR] MÉTHODES DE PRÉVENTION OU DE TRAITEMENT DE L'ATHÉROSCLÉROSE AVEC DES INHIBITEURS D'ISOENZYMES SPÉCIFIQUES DE LA NEURAMINIDASE HUMAINE
  申请人：UNIV ALBERTA

  公开号：WO2018213933A1

  公开（公告）日：2018-11-29

  The present invention provides a method of preventing or treating atherosclerosis or a symptom thereof comprising administering to a subject in need thereof a specific inhibitor of neuraminidase 1 (neu1); neuraminidase 3 (neu3); or a bispecific inhibitor of neu1 or neu3 of formula I; (I) and a compound of formula I.

  本发明提供了一种预防或治疗动脉粥样硬化或其症状的方法，包括向需要的受试者施用神经氨酸酶1（neu1）的特异性抑制剂；神经氨酸酶3（neu3）；或式I的neu1或neu3的双特异性抑制剂；（I）和式I的化合物。
• Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
  申请人：——

  公开号：US20020103203A1

  公开（公告）日：2002-08-01

  Amide compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

  描述了调节和/或抑制特定蛋白激酶活性的酰胺化合物。这些化合物和含有它们的药物组合物能够介导酪氨酸激酶信号传导，以调节和/或抑制不需要的细胞增殖。该发明还涉及含有这些化合物的药物组合物的治疗或预防用途，以及通过给予这些化合物的有效量来治疗癌症以及与不需要的血管生成和/或细胞增殖相关的其他疾病状态，如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和牛皮癣的方法。
• SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF
  申请人：Vakalopoulos Alexandros

  公开号：US20130210795A1

  公开（公告）日：2013-08-15

  The present application relates to novel substituted dicyanopyridines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prophylaxis of cardiovascular disorders.

  本申请涉及新型取代二氰基吡啶，其制备方法，它们用于治疗和/或预防疾病的用途，以及用于制备治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防心血管疾病的用途。
• A novel class of apical sodium co-dependent bile acid transporter inhibitors: The 1,2-Benzothiazepines
  作者：Michael B. Tollefson、Stephen A. Kolodziej、Theresa R. Fletcher、William F. Vernier、Judith A. Beaudry、Bradley T. Keller、David B. Reitz

  DOI：10.1016/j.bmcl.2003.08.004

  日期：2003.11

  2-benzothiazepin-4-ol 1,1-dioxides were prepared and were found to inhibit the apical sodium co-dependent bile acid transporter (ASBT) for the potential treatment for hyperlipidemia. Several 1,2-benzothiazepines exhibited low nanomolar in vitro activity. The synthesis and initial in vitro potency data is presented for this novel class of compounds.

  制备了一系列5-芳基-3,3-二丁基-7-（二甲基氨基）-1,2-苯并噻唑啉-4-醇1,1-二氧化物，发现它们可以抑制心钠钠依赖性胆汁酸转运蛋白（ ASBT）用于高脂血症的潜在治疗。几种1,2-苯并噻氮平在体外具有较低的纳摩尔浓度。提供了这类新型化合物的合成和初始体外效能数据。